Trials / Completed
CompletedNCT02467400
Dose Response and Receptor Selectivity of Beta-blocker Effects on Bone Metabolism
- Status
- Completed
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 165 (actual)
- Sponsor
- Mayo Clinic · Academic / Other
- Sex
- Female
- Age
- 50 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
This study is designed to answer the question as to whether the sympathetic nervous system is an important determinant of bone metabolism in humans.
Detailed description
In postmenopausal women, who have increased sympathetic outflow, to test the hypothesis that treatment with low doses of a non-selective β-blocker (propranolol) will increase serum markers of bone formation and reduce markers of bone resorption (Aim 1a); and using increasingly β1-AR (adrenergic receptor) selective blockers (atenolol and nebivolol), to better define the β-adrenergic receptor selectivity (β1 versus β2) in the regulation of bone turnover by sympathetic outflow in humans.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Atenolol | beta blocker |
| DRUG | Nebivolol | beta blocker |
| DRUG | Propranolol | beta blocker |
| DRUG | placebo | placebo |
Timeline
- Start date
- 2015-07-01
- Primary completion
- 2017-10-26
- Completion
- 2018-04-01
- First posted
- 2015-06-10
- Last updated
- 2019-02-06
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02467400. Inclusion in this directory is not an endorsement.